8% and 100% of patients respectively, while transami-nases were within normal range in 55.6% and 83.3% of patients respectively. A significant reduction in CPT score was observed from 8.84±1.7

at baseline to 7.66±2.24, 6.67±1.68 and 6.50±1.38 at 6, 12 and 24 months, respectively (P=0.003). Vismodegib CPT was >1 0 in 36.4% of the patients at baseline, 21.8% at 6 months, 5.5% at 12 months, and in no patients thereafter. Similarly Modification for End-stage Liver Disease (MELD) score was reduced from 14.22±4.15 at baseline to 13.44±4.45 and 12.06±3.78, at 6 and 12 months, respectively (p=0.018). The mean serum creatinine changed from 0.90±0.20 at baseline to 1.00+0.20, 1.07+0.23, 1.10+0.30 and 1.10+0.23 mg/dl at 12, 24, 26 and 48 months respectively (P=0.81). None of the patients discontinued treatment due to SAEs while in 2 patients the TDF dose was reduced. Three patients died at 2 and 4 months

of follow up because of liver failure and sepsis. All had severe disease (CPT and MELD scores 10.67±1.15 and 17.33±4.04, respectively). Treatment with TDF or ENT offered a significantly better survival rate compared to LAM monotherapy (log-rank test, P=0.02). Conclusions: In patients with selleck chemicals decompensated liver disease due to CHB, long term TDF and ENT monotherapy is well tolerated and associated with an improvement in biochemical, virological and clinical parameters. In these severely ill patients, TDF or ENT monotherapy improves survival when compared to lamivudine monotherapy. However deaths may occur soon after TDF/ETV initiation in patients with severe liver disease. Disclosures: Spilios Manolakopoulos – Advisory Committees or Review Panels: NOVARTIS, ROCHE,

MSD, BMS, GILEAD; Consulting: ROCHE, GILEAD, BMS; Speaking and Teaching: MSD, GILEAD, BMS Melanie Deutsch – Consulting: MSD George V. Papatheodoridis – Advisory Committees or Review Panels: Janssen, Abbott, Boehringer, Novartis, BMS, Gilead, Roche; Consulting: Roche; Grant/Research Support: BMS, Gilead, Roche; Speaking and Teaching: Janssen, Novartis, BMS, Gilead, Roche, MSD The following people have nothing to disclose: Christos K. Triantos, Nikoletta Mathou, Maria medchemexpress Mela, Athanasia Striki, Maria Kalafateli, Georgios Kontos, Hariklia Kranidioti, Emanuel K. Manesis Objectives: To evaluate the efficacy and safety of telbivudine in preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in HBeAg-positive pregnant women with high viral load. Methods: We investigated the effect of telbivudine in preventing MTCT of HBV in an open-label study since 2008. A total of 232 HBeAg-positive pregnant women with HBV DNA levels≧106 IU/mL received telbivudine 600 mg daily from 24 to 33 weeks of gestation, and 153 pregnant women with the same situation who were unwilling to take antiviral drugs were served as untreated controls. Each infant of both groups was vaccinated with recombinant HBV vaccine and injected with hepatitis B immune globulin (HBIG) according to standard routine methods.